Comparative Pharmacology
Head-to-head clinical analysis: BROVANA versus XOPENEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROVANA versus XOPENEX.
BROVANA vs XOPENEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BROVANA (arformoterol tartrate) is a long-acting beta2-adrenergic agonist (LABA). It stimulates intracellular adenyl cyclase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Selective beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP levels.
15 mcg (2 mL) by nebulization twice daily, not to exceed 30 mcg/day.
Nebulized solution: 0.63 mg or 1.25 mg 3 times daily every 6-8 hours; metered-dose inhaler: 2 inhalations (90 mcg per inhalation) 3 times daily every 6-8 hours.
None Documented
None Documented
Terminal elimination half-life: approximately 26 hours (range 22–30 hours) in healthy adults; prolonged in hepatic impairment (up to 50% increase).
Terminal elimination half-life: 3.3-4.0 hours in adults. Clinically, twice-daily dosing is not recommended due to shorter half-life; every 4-6 hour dosing is standard for acute bronchodilation.
Primarily renal (60% unchanged drug); remainder via biliary/fecal (approximately 20%) and metabolic transformation.
Renal: 80-100% as unchanged drug and metabolites (approximately 60% as unchanged levalbuterol, 20% as inactive sulfate conjugate). Fecal: <5%.
Category C
Category C
Bronchodilator
Bronchodilator